.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

ePoster
eP143

A Phase 3 trial of fixed dose combination of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma

Appointment

Date: 25/09/2024

Time: 09:00 – 09:00

Talk time: 0 Min.

Discussion time: 0 Min.

Location / Stream:

ePoster Selbststudium 3

Poster

A Phase 3 trial of fixed dose combination of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma

Session

Selbststudium: Melanom

Authors

Nikhil I. Khushalani (Tampa, FL, US), Jayakumar Mani (Tarrytown, NY, US), Jocelyn Booth (Tarrytown, NY, US), Zoe Zhang (Tarrytown, NY, US), Mark Salvati (Tarrytown, NY, US), Israel Lowy (Tarrytown, NY, US), Matthew G. Fury (Tarrytown, NY, US), Karl Lewis (Tarrytown, NY, US), Garen Manvelian (Tarrytown, NY, US), Hussein A. Tawbi (Houston, TX, US)